Kinase modulators and methods of use

US8076338B2 · kind B2 · utility

Assignee

• Exelixis, Inc. · US

Inventors

• Neel K. Anand · Burlingame, US
• Charles M. Blazey · San Francisco, US
• Owen Joseph Bowles · Pacifica, US
• Joerg Bussenius · Foster City, US
• Lynne Canne Bannen · Lucerne, US
• Diva Sze-Ming Chan · San Francisco, US
• Baili Chen · Palo Alto, US
• Erick Wang Co · San Diego, US
• Simona Costanzo · Los Altos, US
• Steven Charles DeFina · Oakland, US
• Larisa Dubenko · San Francisco, US
• Maurizio Franzini · San Francisco, US
• Ping Huang · Mountain View, US
• Vasu Jammalamadaka · Irvine, US
• Richard George Khoury · Redwood City, US
• Moon Hwan Kim · Palo Alto, US
• Rhett Ronald Klein · Chicago, US
• Donna Tra Le · San Jose, US
• Morrison B. Mac · San Francisco, US
• John M. Nuss · Danville, US
• Jason Jevious Parks · Sacramento, US
• Kenneth D. Rice · San Rafael, US
• Tsze H. Tsang · Corona, US
• Amy Lew Tsuhako · Milpitas, US
• Yong Wang · South San Francisco, US
• Wei Xu · Saginaw, US

Key dates

• Filing date: Apr 22, 2005
• Grant date: Dec 13, 2011
• Expiry date: Dec 7, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the Formula (I) and (II) wherein R, R21, R25-R33, m, n, X21-X23, and Q1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.